Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
PHARMACYCLICS INC (PCYC) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/26/2015 8-K Form 8-K - Current report
05/01/2015 8-K Quarterly results
Docs: "Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates"
03/23/2015 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
03/16/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "Independent Data Monitoring Committee Unanimously Recommends Unblinding of IMBRUVICA® (ibrutinib) Phase III Combination HELIOS Trial Based on Interim Analysis Showing Significant Improvement in Progression-Free Survival in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma"
03/06/2015 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Agreement and Plan of Reorganization, by and among by and among AbbVie Inc., Oxford Amherst Corporation, Oxford Amherst LLC and Pharmacyclics, Inc",
"Amendment to Amended and Restated Bylaws of Pharmacyclics, Inc",
"Support Agreement",
"Form of Pharmacyclics, Inc. Change in Control and Severance Plan"
03/05/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "NORTH CHICAGO, Ill. and SUNNYVALE, Calif., March 4, 2015"
02/20/2015 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "February 18, 2015 Earnings Call Transcript"
02/18/2015 8-K Quarterly results
Docs: "- Reaffirms 2015 U.S. Product Revenue Guidance -"
02/02/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "U.S. FDA Approves IMBRUVICA® (ibrutinib) for Treatment of Waldenstrom’s macroglobulinemia (WM)"
01/23/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/20/2015 8-K Regulation FD Disclosure
01/12/2015 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Pharmacyclics Announces Preliminary 2014 U.S. Net Product Revenue Results and 2015 U.S. Net Product Revenue Outlook"
01/12/2015 8-K Investor presentation
Docs: "J.P. Morgan Healthcare Conference Presentation"
12/10/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Pharmacyclics Announces Launch of informCLL™ Registry for Chronic Lymphocytic Leukemia Patients U.S.-Based Registry Will Enhance Clinical Knowledge of and Explore Treatment Options for CLL Patients",
"IMBRUVICA (IBRUTINIB) DATA SUGGESTS PROMISE IN MULTIPLE MYELOMA",
"IMBRUVICA® in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy · Note: This press release corresponds to abstracts 627 and 1998.",
"Longer Follow-Up IMBRUVICA® Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia Data Show 84% Progression-Free Survival Rate at One Year and Improvement in Quality of Life · Note: This press release corresponds to abstracts 327, 3331 and 4696.",
"IMBRUVICA® Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in Mantle Cell Lymphoma"
12/01/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "New IMBRUVICA® (ibrutinib) Application Accepted by European Medicines Agency for Waldenstrom’s Macroglobulinemia"
11/26/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/12/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "November 4, 2014 Earnings Call Transcript"
11/06/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Summary of Oral Presentations, which relate to Pharmacyclics, Inc.’s products at the American Society of Hematology Annual Meeting"
11/06/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "IMBRUVICA® Data to be Presented Across Multiple Histologies, Including in Eight Oral Presentations, at 2014 American Society of Hematology Annual Meeting More than 37 IMBRUVICA Data Abstracts Will be Presented"
11/04/2014 8-K Quarterly results
Docs: "Pharmacyclics Reports Third Quarter 2014 Financial Results and Provides Clinical Program Update"
10/20/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "IMBRUVICA® (ibrutinib) Now Approved in Europe for Treatment of Two Blood Cancers"
09/30/2014 8-K Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Pan-HDAC Inhibitor Collaboration Sunnyvale, CA, and Suresnes, France, September 25, 2014"
08/29/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/08/2014 8-K Other Events
08/01/2014 8-K Investor presentation
Docs: "July 31, 2014 Earnings Call Transcript",
"0 500 1000 1500 2000 2500 3000 3500"
07/31/2014 8-K Quarterly results
Docs: "Pharmacyclics Reports Second Quarter 2014 Results"
07/30/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "July 28, 2014 Conference Call Transcript",
"Previously Treated Chronic Lymphocytic Leukemia Based on Statistically Significant Progression-Free and Overall Survival Benefits Del 17P CLL, Only FDA-Approved Agent"
06/05/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "IMBRUVICA SIGNIFICANTLY IMPROVES",
"IMBRUVICA SHOWS DURABLE",
"IMBRUVICA COMBINATION",
"Oral presentation entitled “Independent Evaluation of Ibrutinib Efficacy 3 Years Post-Initiation of Monotherapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia Including Deletion 17p Disease”",
"Oral presentation entitled “Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Phase III RESONATETM Trial”"
05/23/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/15/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Pharmacyclics Highlights Important New Data for IMBRUVICA® in B-Cell Malignancies Initial Presentation of Phase III RESONATETM study and updated results in CLL of single agent IMBRUVICA and also CD20 combination to be presented during ASCO May 30 - Jun 3, 2014"
05/14/2014 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "2014 Equity Incentive Award Plan"
05/06/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "May 2, 2014 Earnings Call Transcript"
05/02/2014 8-K Quarterly results
Docs: "Pharmacyclics Reports First Quarter 2014 Results"
04/21/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Pharmacyclics Announces Presentation of Phase III and Long Term Follow Up Data on"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy